xendou
famili
includ
sever
protein
varieti
organ
rang
virus
far
xenopu
laevi
xendou
well
human
homologu
placent
protein
viral
homologu
nendou
character
endoribonucleas
particip
event
enzym
produc
molecul
termini
uniqu
characterist
particular
class
rnase
addit
phylogenet
structur
studi
indic
one
conserv
region
share
three
protein
includ
put
activ
site
display
common
architectur
may
involv
differ
rna
process
member
famili
annot
put
serin
proteas
nevertheless
high
evolutionari
conserv
character
rnase
suggest
may
endoriboucleolyt
activ
well
previou
identifi
character
xendou
found
member
famili
enzym
involv
endonucleolyt
process
small
nucleolar
rna
snorna
class
noncod
rna
play
essenti
role
ribosom
second
member
describ
viral
homologu
call
major
genet
marker
nidovirus
includ
coronaviru
caus
sever
acut
respiratori
syndrom
sar
nendou
crucial
viabil
virus
mutat
singl
residu
within
put
activ
site
abolish
viral
rna
recent
human
homologu
despit
annot
function
put
serin
endoribonucleas
activ
placent
tissu
addit
express
differ
tumor
breast
cancer
testicular
gastric
cancer
dysregul
express
tumor
tissu
suggest
may
associ
due
involv
human
patholog
enzym
repres
potenti
target
develop
therapeut
agent
focus
identif
valid
small
molecul
may
function
specif
inhibitor
class
enzym
aim
chose
xendou
model
system
sever
reason
crystallograph
structur
use
drug
design
ie
virtual
screen
recombin
protein
display
enzymat
featur
nativ
enzym
vitro
function
test
distinguish
enzym
bind
catalyt
activ
alreadi
combin
virtual
screen
experiment
analys
identifi
four
compound
specif
inhibit
catalyt
activ
xendou
low
micromolar
rang
addit
molecular
dock
experi
suggest
compound
might
also
bind
activ
site
nendou
inhibit
abolish
viral
replic
xendou
crystal
structur
reveal
presenc
phosphat
bound
helix
iii
site
crucial
catalyt
tent
approach
valid
correspond
phosphat
locat
potenti
catalyt
site
blind
dock
simul
conduct
use
autodock
previous
report
present
dock
experi
uridin
uridin
uracil
dimer
uu
uracil
trimer
uuu
tetram
cuug
use
turn
substratesligand
interestingli
favor
bound
conform
predict
ie
lowest
energi
complex
includ
ligand
dock
proxim
phosphat
bind
site
figur
particular
predict
posit
phosphat
overlap
quit
well
experiment
determin
bound
phosphat
support
inform
figur
although
pyrimidin
moieti
differ
orient
discrep
predict
experiment
bind
mode
probabl
due
limit
autodock
treat
cycl
flexibl
fact
dock
studi
conform
constrain
program
unabl
find
altern
bind
mode
compar
substratesligand
figur
howev
forc
adopt
similar
bind
mode
would
result
high
energi
complex
data
shown
notabl
predict
bound
conform
uu
uuu
cuug
confirm
posit
activ
site
region
helix
iii
may
explain
report
cleavag
activ
middl
uu
pair
support
inform
figur
virtual
screen
driven
approach
widespread
lead
identif
method
pharmaceut
best
result
normal
obtain
combin
differ
virtual
screen
method
use
inform
drug
target
well
known
ligand
unfortun
inform
regard
known
ligand
avail
present
studi
therefor
multidock
approach
use
consensu
dock
method
appli
databas
compound
list
us
nation
cancer
institut
nci
divers
set
librari
repres
larger
collect
approxim
chemic
among
avail
dock
attent
focus
free
academ
program
among
select
basi
differ
implement
dock
algorithm
success
unlik
protocol
report
miteva
et
consensu
dock
protocol
use
see
experiment
section
detail
conduct
use
four
dock
method
parallel
consensu
score
appli
rank
overal
obtain
pose
support
inform
figur
multidock
approach
allow
us
select
compound
potenti
inhibitori
function
molecul
list
nci
divers
set
compound
experiment
test
biolog
activ
use
vitro
cleavag
typic
assay
carri
incub
enzym
rna
substrat
presenc
manganes
analyz
product
cleavag
differ
time
reaction
snorna
primari
transcript
rna
mimick
natur
xendou
substrat
sourc
enzymat
activ
use
recombin
version
xendou
xendou
display
biochem
featur
nativ
cleavag
assay
carri
dmso
concentr
allow
compound
solubl
without
affect
xendou
cleavag
activ
data
shown
figur
show
cleavag
reaction
carri
presenc
seven
best
perform
agent
affect
xendou
activ
differ
micromolar
concentr
nsc
nsc
nsc
almost
complet
abolish
endoribonucleolyt
activ
higher
concentr
demonstr
absenc
specif
cleavag
product
figur
notabl
nsc
nsc
nsc
nsc
inhibit
activ
lower
concentr
figur
tabl
analysi
perform
shorter
rna
substrat
oligoribonucleotid
contain
two
xendou
cleavag
confirm
inhibitori
effect
compound
indic
activ
depend
length
rna
substrat
support
inform
figur
addit
exclud
possibl
compound
interact
nonspecif
recombin
protein
assay
carri
x
laevi
oocyt
nuclear
extract
one
contain
xendou
nativ
result
obtain
one
activ
compound
nsc
confirm
inhibitori
activ
independ
presenc
support
inform
figur
determin
whether
seven
identifi
inhibitor
interfer
xendou
cleavag
andor
bind
activ
test
abil
hamper
interact
vitro
bind
assay
carri
use
recombin
enzym
rna
substrat
shorter
version
rna
chose
rna
substrat
sinc
length
allow
format
stabl
recombin
xendou
incub
radiolabel
rna
absenc
presenc
fix
concentr
inhibitor
assembl
complex
visual
electrophoret
mobil
shift
assay
shown
figur
c
percentag
shift
rna
repres
rna
fraction
assembl
protein
affect
presenc
inhibitor
suggest
compound
influenc
interact
establish
whether
action
compound
select
test
unrel
endoribonucleas
rnase
rnase
specif
degrad
rna
cytosin
uracil
guanin
respect
enzym
incub
radiolabel
rna
substrat
presenc
test
compound
maximum
concentr
result
show
neither
rnase
rnase
activ
affect
high
drug
concentr
support
inform
figur
thu
impli
select
predict
bind
mode
seven
xendou
inhibitor
identifi
librari
compound
visual
inspect
bind
mode
predict
four
dock
program
use
virtual
screen
protocol
good
agreement
one
anoth
figur
noteworthi
lower
half
maxim
inhibitori
concentr
valu
correl
improv
agreement
four
predict
bind
conform
hit
compound
fact
increas
conform
disord
associ
decreas
inhibitori
activ
agreement
observ
tighter
interact
predict
enzym
inhibitor
nsc
nsc
nsc
wherea
weakest
interact
predict
form
least
activ
compound
nsc
subsequ
energi
calcul
indic
dock
conform
propos
autodock
display
lowest
energi
consequ
use
program
analysi
diagram
autodock
pose
inhibitor
show
extend
network
predict
interact
activ
molecul
network
reduc
inhibitor
nsc
least
activ
agent
predict
least
number
interact
support
inform
figur
analysi
autodock
predict
bind
mode
led
definit
specif
area
associ
inhibitori
activ
compound
support
inform
figur
extend
hydrophob
interact
purpl
area
support
inform
figur
less
activ
compound
seem
compens
lack
strong
interact
compar
ligplot
diagram
support
inform
figur
interact
profil
allow
us
defin
ligand
surfac
import
xendou
inhibit
particular
analysi
molecular
featur
identifi
hit
led
definit
pharmacophor
model
made
six
point
describ
minim
chemic
characterist
requir
xendou
inhibit
figur
four
name
deriv
activ
inhibitor
two
relat
less
potent
compound
hydrophob
featur
present
seven
compound
consid
core
pharmacophor
scaffold
although
make
import
interact
xendou
residu
connect
hydrogen
acceptor
miss
least
activ
compound
nsc
oxygen
atom
nitro
sulfon
group
overlap
phosphat
found
xendou
crystal
mainli
involv
interact
ie
hydrogen
bond
predict
bind
pocket
form
charg
residu
arg
asn
thr
support
inform
figur
second
hydrophob
featur
compris
aromat
aromat
ring
featur
present
compound
partial
present
nsc
benzothiazol
benzen
ring
shift
away
aromat
ring
slightli
larger
involv
hydrophob
interact
larg
pocket
form
side
chain
portion
ly
pro
tyr
fourth
main
featur
present
activ
compound
repres
oxygen
atom
nitro
nsc
nsc
ring
nsc
found
distanc
first
supplementari
featur
specif
weakli
activ
nsc
nsc
repres
aromat
moieti
fill
hydrophob
pocket
form
met
trp
ly
side
chain
last
featur
present
less
activ
compound
defin
pyridin
anilin
nsc
nsc
respect
occupi
small
pocket
delimit
portion
ly
asn
arg
residu
extend
investig
member
xendou
famili
monitor
effect
inhibitor
human
homologu
recombin
enzym
incub
radiolabel
rna
presenc
compound
maximum
concentr
shown
figur
four
seven
molecul
nsc
nsc
nsc
nsc
inhibit
activ
inhibitori
activ
compound
investig
lower
concentr
shown
figur
b
nsc
display
strongest
inhibitori
activ
determin
six
concentr
xendou
mobil
shift
assay
show
activ
compound
impair
catalyt
activ
figur
c
final
investig
possibl
bind
mode
four
activ
inhibitor
nsc
nsc
nsc
nsc
autodock
appli
recent
report
homolog
similar
observ
xendou
blind
dock
procedur
pose
four
inhibitor
overlap
region
figur
notabl
identifi
bind
area
coincid
previous
report
activ
site
interact
profil
four
inhibitor
report
ligplot
diagram
support
inform
figur
due
structur
similar
xendou
famili
member
avail
structur
inform
extend
dock
protocol
includ
viral
homologu
nendou
pdb
check
bind
mode
analog
inhibitor
activ
xendou
enzym
strikingli
blind
dock
autodock
procedur
perform
nendou
posit
four
compound
bind
region
correspond
activ
site
figur
furthermor
bind
conform
nsc
activ
compound
xendou
nendou
similar
observ
two
protein
even
though
three
orient
fulli
superimpos
figur
c
endoribonucleas
consid
key
player
gener
process
associ
eukaryot
rna
metabol
variou
subcellular
compart
involv
degrad
pathway
rna
turnov
matur
pathway
produc
function
rna
xendou
endoribonucleas
discov
purifi
x
laevi
character
activ
indic
x
laevi
germ
cell
respons
releas
snorna
primari
transcript
small
noncod
rna
requir
rrna
modif
turn
essenti
ribosom
biogenesi
function
howev
whether
xendou
play
differ
addit
function
somat
cell
still
unexplor
subsequ
product
recombin
xendou
protein
allow
us
character
activ
pursu
biochem
structur
studi
structur
xendou
solv
descript
activ
site
compar
rna
process
enzym
indic
display
uniqu
xendou
propos
found
member
previous
unidentifi
protein
phylogenet
analys
highlight
xendou
conserv
among
higher
eukaryot
homologu
nidovirus
cyanobacterium
despit
high
conserv
activ
site
architectur
endoribonucleolyt
function
prove
three
member
famili
wherea
member
annot
put
serin
proteas
still
uncharacter
human
viral
enzym
link
human
patholog
tumor
respiratori
diseas
therefor
identif
small
molecul
specif
interfer
activ
may
repres
first
step
toward
develop
novel
therapeut
treatment
took
advantag
experi
set
virtual
screen
approach
allow
us
select
nci
divers
set
small
molecul
potenti
endow
enzym
inhibitori
function
reason
main
characterist
molecul
abil
locat
insid
conserv
activ
preliminari
dock
simul
use
autodock
appli
xendou
use
variou
known
substrat
method
confirm
locat
xendou
activ
site
region
helix
iii
previous
determin
biochem
crystallograph
second
step
virtual
screen
achiev
multidock
approach
deriv
combin
autodock
dock
method
approach
appli
nci
divers
set
led
select
molecul
compound
display
potenti
inhibitori
featur
molecul
experiment
test
x
laevi
human
recombin
enzym
four
inhibitor
effect
impair
catalyt
activ
endoribonucleas
affect
interact
result
support
previou
conclus
xendou
rna
bind
process
activ
function
reveal
compound
bind
activ
site
conclus
confirm
effect
inhibitor
xendou
enzym
noteworthi
found
good
agreement
experiment
virtual
screen
data
fact
molecul
display
highest
inhibitor
activ
xendou
name
nsc
nsc
nsc
establish
extend
network
interact
accordingli
less
activ
compound
display
reduc
number
interact
exploit
xendou
inhibitor
characterist
allow
us
produc
pharmacophor
model
carri
essenti
featur
requir
inhibit
enzymat
activ
repres
first
step
design
new
molecul
inhibitor
entir
xendou
famili
studi
also
extend
character
member
xendou
famili
viral
nendou
enzym
although
experiment
evid
yet
avail
dock
simul
posit
four
activ
compound
nendou
region
correspond
activ
result
unexpect
sinc
catalyt
domain
share
three
enzym
conserv
structur
sequenc
suggest
inhibitor
report
could
also
act
coronaviru
nendou
inhibitor
thu
potenti
antivir
compound
could
interfer
infecti
viru
life
cycl
mandatori
requir
inhibitor
specif
demonstr
featur
fulli
accomplish
select
compound
sinc
affect
catalyt
activ
endoribonucleas
rnase
even
high
concentr
observ
select
molecul
local
conserv
activ
site
three
endoribonucleas
open
new
perspect
investig
aim
predict
activ
site
unveil
function
member
xendou
famili
may
flexibl
involv
crucial
rna
process
pathway
moreov
due
substrat
specif
inhibitor
identifi
could
also
repres
lead
compound
develop
new
candid
antivir
agent
protein
prepar
three
enzym
monom
present
xendou
coordin
retriev
protein
databank
pdb
within
put
phosphat
bind
site
residu
arg
exhibit
two
differ
side
chain
conform
togeth
inform
give
six
differ
xendou
conform
due
steric
hindranc
gener
upon
hydrogen
atom
addit
six
xendou
structur
geometr
optim
use
amber
molecular
model
suit
aim
structur
solvat
solvateoct
command
box
extend
water
molecul
model
neutral
na
ion
solvat
complex
refin
minim
interact
use
sander
modul
amber
graphic
inspect
minim
model
imag
produc
use
univers
california
san
francisco
ucsf
chimera
packag
version
resourc
biocomput
visual
informat
ucsf
support
us
nation
institut
health
grant
atom
charg
assign
protein
leap
modul
maintain
subsequ
dock
simul
protocol
use
nendou
structur
prepar
describ
subsequ
dock
simul
six
xendou
conform
use
cross
dock
thu
includ
protein
mobil
extent
dock
ligand
prepar
structur
uu
uuu
cuug
prepar
start
ascii
text
use
standalon
version
prodrg
version
conjunct
gromac
suit
version
virtual
screen
us
nation
cancer
institut
divers
set
http
dtpncinihgov
databas
consist
compound
use
autodock
dock
perform
use
autodock
version
previous
compound
propos
pose
cluster
describ
autodock
manual
substrat
dock
grid
embrac
whole
xendou
protein
use
center
protein
mass
center
virtual
screen
smaller
grid
use
compris
protein
residu
within
experiment
determin
phosphat
grid
center
phosphor
atom
phosphat
group
total
run
perform
enzym
dock
version
use
dock
appli
algorithm
fit
ligand
atom
sphere
bind
pocket
sphgen
includ
dock
use
creat
overlap
sphere
within
radiu
complementar
protein
surfac
connolli
surfac
bind
pocket
gener
use
dm
includ
dock
probe
radiu
bind
pocket
includ
receptor
residu
distanc
atom
phosphat
exampl
dock
input
file
given
tabl
support
inform
surflex
program
version
implement
hammerhead
methodolog
describ
welch
et
similar
predecessor
gener
site
call
protomol
fragment
individu
ligand
align
protomol
order
yield
pose
maxim
molecular
complementar
bind
site
definit
protomol
sensit
step
dock
perform
depend
area
consid
form
bind
site
far
potenti
ligand
site
extend
well
deep
protein
atom
probe
use
defin
protomol
penetr
protomol
gener
use
xendou
protein
subset
compris
residu
within
bound
phosphat
omegafr
fred
version
requir
set
conform
ligand
conform
gener
use
omega
version
store
singl
binari
file
conform
gener
set
see
tabl
support
inform
fred
dock
consist
four
step
exhaust
dock
optim
consensu
structur
option
refin
exhaust
dock
pose
ensembl
gener
rigidli
rotat
translat
conform
within
activ
site
activ
site
defin
box
default
extens
direct
phosphat
detail
dock
setup
report
tabl
support
inform
consensu
dockingscor
top
score
pose
molecul
dock
experi
compar
mean
root
mean
squar
deviat
rmsd
atom
posit
rank
order
compound
lowest
rmsd
valu
rank
highest
consensu
dock
comparison
score
score
function
perform
simpl
addit
rank
order
dock
consensu
dock
reorder
compound
lowest
highest
total
rank
final
sum
rank
order
two
consensu
dock
procedur
final
rank
obtain
top
rank
molecul
select
obtain
us
nation
cancer
institut
see
tabl
support
inform
prepar
inhibitor
inhibitor
dissolv
dmso
give
final
concentr
accord
experiment
requir
dilut
solvent
ensur
fix
concentr
dmso
reaction
mixtur
vitro
rna
transcript
rna
describ
refer
synthes
vitro
transcript
presenc
utp
accord
literatur
process
assay
cpm
precursor
correspond
fmol
incub
ng
purifi
mm
mm
nacl
mm
hepe
ph
mm
dithiothreitol
escherichia
coli
trna
u
rnase
inhibitor
ge
healthcar
dmso
presenc
decreas
amount
rang
specif
inhibitor
min
parallel
rna
process
assay
also
carri
xenopu
laevi
oocyt
nuclear
extract
one
contain
xendou
nativ
presenc
nsc
activ
xendou
reaction
product
extract
analyz
polyacrylamid
urea
gel
acrylamidebi
oligoribonucleotid
label
atp
perkinelm
life
scienc
incub
ng
ng
ng
rnase
use
condit
describ
reaction
product
analyz
polyacrylamid
urea
gel
rnase
assay
label
substrat
incub
min
u
enzym
mm
edta
mm
trishcl
ph
dmso
bind
reaction
bind
assay
perform
incub
fmol
utp
perkinelm
life
scienc
vitro
transcrib
mini
rna
ng
recombin
protein
xendou
final
volum
bind
buffer
mm
hepe
ph
mm
nacl
mm
ethylen
glycol
tetraacet
acid
egta
mm
dithiothreitol
glycerol
u
rnase
inhibitor
dmso
min
incub
complex
fraction
polyacrylamid
nativ
gel
acrylamid
bi
contain
glycerol
visual
autoradiographi
calcul
inhibitori
activ
individu
compound
evalu
percentag
uncleav
rna
substrat
versu
input
rna
express
half
maxim
inhibitori
concentr
valu
determin
nonlinear
fit
strategi
perform
use
prism
version
graphpad
softwar
inc
san
diego
ca
usa
